Developer docs
API playgroundTry for free, no card

Search company profiles

Juvena Therapeutics

Full company profile

uuid000045f

Namestring
Juvena Therapeutics
Legal namestring
Juvena Therapeutics Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Juvena Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Redwood City, California, developing tissue-restorative biologics for chronic muscle and age-related conditions including Myotonic Dystrophy Type 1, sarcopenia, obesity, idiopathic pulmonary fibrosis, and fibrotic liver disease. The company operates a proprietary AI-enabled discovery platform called JuvNET that integrates a multi-dimensional protein library mined from human pluripotent stem cell secretomes, in silico mapping of secreted proteins to disease phenotypes, in vitro human cell screening, in vivo pharmacology, and protein engineering, supported by quantitative proteomics, transcriptomics, robotics-enabled high-content imaging, and machine learning/deep learning models. All pipeline assets are sourced from this platform, including the clinical-stage lead JUV-161 (a first-in-class muscle-regenerating fusion protein with FDA Orphan Drug Designation for DM1, currently in Phase 1 trials and being expanded into sarcopenia), the preclinical metabolic program JUV-112 (an obesity biologic acting via lipid metabolism), and earlier-stage programs in IPF and hepatic disease.

Short descriptiontext

Juvena Therapeutics is a clinical-stage biotechnology company that uses its AI-enabled JuvNET platform to engineer tissue-restorative biologics from stem-cell secreted proteins, targeting myopathies and age-related metabolic and degenerative diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tissue-restorative biologics, AI-enabled biologics discovery, regenerative biopharmaceuticals, protein engineering platform, muscle regeneration therapeutics
Industry2 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Research Collaboration and Partnership Milestones
TypeLicensing Royalties
Description

Pharmaceutical partnership milestone payments from research collaborations, exemplified by the Eli Lilly research collaboration agreement valued at over $650 million in potential milestone payments, focused on muscle health, body composition, and metabolic disease. Includes upfront payments, R&D funding, and contingent milestone payments plus potential royalties.

businesswire.com
2Future Biologics Product Sales (Pre-Commercial)
TypeOne Time License
Description

Future revenue from commercialization of tissue-restorative biologics (JUV-161 for Myotonic Dystrophy Type 1 and sarcopenia, JUV-112 for obesity/metabolic disease). Currently pre-commercial / clinical-stage with Phase 1 studies underway; no product sales revenue yet.

businesswire.com
3Non-Dilutive Grant Funding
TypeManaged Services
Description

Non-dilutive grant funding from institutions including the California Institute for Regenerative Medicine (CIRM) - $3,906,376 TRAN1 grant - and NIH/National Institute on Aging support to advance lead programs and platform research.

biospace.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1JuvNET Platform
Description

Juvena's proprietary AI-enabled end-to-end biologics drug discovery and development platform that maps secreted proteins to specific disease phenotypes, combining in silico, in vitro, in vivo, and protein engineering capabilities.

juvenatherapeutics.com
Core offering1 text field

Juvena Therapeutics is a computationally-driven biopharmaceutical company that develops tissue-restorative biologics to treat myopathies and metabolic diseases. The company operates an AI-enabled discovery and development platform (JuvNET) that mines proteins secreted by human stem cells, maps them to disease phenotypes, and engineers novel biologic medicines, with a lead clinical-stage asset (JUV-161) targeting Myotonic Dystrophy Type 1 and sarcopenia, plus preclinical programs in obesity/metabolic disease (JUV-112), idiopathic pulmonary fibrosis, and fibrotic liver disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Completed dosing in 5 of 6 SAD cohorts and all MAD cohorts in Phase 1 JUV-161 study by January 2026
+4 more records
Product overview1 text field

Juvena Therapeutics offers a platform-plus-pipeline architecture anchored by a single core technology — the AI-enabled JuvNET Platform — from which all of its discrete clinical and preclinical biologic assets are derived. The JuvNET Platform mines thousands of proteins secreted by human stem cells and systematically maps them to specific disease phenotypes using AI, quantitative proteomics, multi-omics, robotics-enabled high-content imaging, and protein engineering to produce tissue-restorative biologics. From this shared platform, Juvena has independently advanced a portfolio of named assets including the clinical-stage lead JUV-161 (a muscle-regenerating fusion protein in Phase 1 for Myotonic Dystrophy Type 1 with FDA Orphan Drug Designation), the preclinical metabolic program JUV-112 (an obesity asset acting via lipid metabolism), and earlier-stage programs in idiopathic pulmonary fibrosis and fibrotic liver disease. All pipeline assets are discovered and produced through the proprietary JuvNET platform and are targeted at myopathies, metabolic diseases, and broader chronic / age-related degenerative conditions.

Product and service2 records
1JuvNET Platform
CategoryDrug discovery platform / core technology
Description

AI-enabled, fully integrated biologics discovery and development platform that mines thousands of proteins secreted by human stem cells, screens their therapeutic potential across disease phenotypes using quantitative proteomics, multi-omics, and robotics-enabled high-content imaging, and engineers novel biologic medicines. Offered to biopharma partners for research collaborations and licensing.

2JUV-161
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagship - Flagship Biopharma Partnership Validating PlatformTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Research collaboration agreement focused on muscle health, body composition, and metabolic disease, valued at over $650 million in potential milestone payments plus tiered royalties. Leverages Juvena's AI-enabled JuvNET platform and secreted protein discovery capabilities to develop novel therapeutics for muscle and metabolic indications. Featured in Nature Biotechnology for enhancing muscle health and body composition. Eli Lilly also participated in Juvena's $33.5M Series B financing in January 2026.

2Myotonic Dystrophy Foundation
Strategic tierCore - Flagship Patient Advocacy Collaboration For Lead IndicationTypeStrategic or Co-development Partner
Description

Juvena works together with the Myotonic Dystrophy Foundation to translate research into tangible clinical benefits for people living with DM1. The collaboration synergizes Juvena's scientific innovations with the Foundation's extensive roots in the Myotonic dystrophy community to enable profound real-world impact. CEO Dr. Tanya Stevenson of MDF endorses Juvena's approach. Joint industry presentations at MDF Annual Conference and regional summits.

juvenatherapeutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Clinical-stage oncology biotech that grew out of a Tri-Institutional Therapeutics Discovery Institute initiative combining academic drug discovery with computational biology. Comparable as a clinical-stage biotech with strong institutional backing that has used innovative discovery approaches to advance targeted therapeutics — though focused on oncology rather than regenerative biologics.

TypeDirect peer
Description

Clinical-stage regenerative medicine biotech developing programmed cellular therapies from induced pluripotent stem cells. Comparable as a clinical-stage company mining stem-cell biology for novel therapeutics, though Fate's modality is cell therapy rather than engineered biologics.

TypeDirect peer
Description

Clinical-stage biotech using AI and omics data to develop therapeutics for age-related diseases, with focus on metabolic and muscle health. Directly comparable given the shared longevity-and-muscle therapeutic focus, AI-platform approach, and clinical stage status.

TypeBroad incumbent
Description

Public cell-engineering platform company that programs biological organisms for diverse applications. Comparable as a platform-plus-services biotech using AI and high-throughput biology, though Ginkgo is a much larger, broader, and more diversified incumbent focused on cell engineering rather than protein therapeutics.

TypeBroad incumbent
Description

Public clinical-stage biotech operating a large-scale AI-enabled drug discovery platform integrating high-throughput biology, chemistry, and ML. Comparable in platform-plus-pipeline architecture, although Recursion is a larger, public, broad-spectrum incumbent with deeper capital and broader indication coverage.

TypeDirect peer
Description

Clinical-stage biotech developing tissue-specific regenerative biologics targeting the Wnt pathway. Highly comparable in regenerative-biologics thesis, with overlap in target disease areas (hepatic, ocular) and at least one shared former team member (Priya Handa).

TypeBroad incumbent
Description

Public AI-enabled antibody discovery platform with partnership-based revenue (including major pharma collaborations). Comparable in combining an AI-driven biologics discovery engine with a partnership-centric business model, although AbCellera's focus is antibodies rather than secreted-protein-derived biologics.

TypeDirect peer
Description

AI-driven drug discovery platform combining machine learning, high-throughput biology, and engineered human disease models to discover novel therapeutics. Directly comparable as a clinical-stage biotech using proprietary AI/ML infrastructure to systematically map biology-to-therapeutics, though Insitro focuses more on small molecules and hepatology/neuroscience rather than biologics.

TypeDirect peer
Description

Clinical-stage biotech developing biologics targeting the TGFβ superfamily for muscle-related and rare diseases, including spinal muscular atrophy and obesity. Comparable as a clinical-stage biologics company pursuing muscle therapeutics — directly relevant given Juvena's JUV-161 sarcopenia program.

TypeDirect peer
Description

Generative AI biologics company using machine learning to design novel protein therapeutics de novo. Closest direct peer given the shared thesis that AI can systematically generate or engineer biologics — a precursor and parallel to Juvena's protein-library-plus-AI approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Juvena Therapeutics

Regenerative Biopharmaceuticalsjuvenatherapeutics.com

Juvena Therapeutics is a clinical-stage biotechnology company that uses its AI-enabled JuvNET platform to engineer tissue-restorative biologics from stem-cell secreted proteins, targeting myopathies and age-related metabolic and degenerative diseases.

What Juvena Therapeutics does

Juvena Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Redwood City, California, developing tissue-restorative biologics for chronic muscle and age-related conditions including Myotonic Dystrophy Type 1, sarcopenia, obesity, idiopathic pulmonary fibrosis, and fibrotic liver disease. The company operates a proprietary AI-enabled discovery platform called JuvNET that integrates a multi-dimensional protein library mined from human pluripotent stem cell secretomes, in silico mapping of secreted proteins to disease phenotypes, in vitro human cell screening, in vivo pharmacology, and protein engineering, supported by quantitative proteomics, transcriptomics, robotics-enabled high-content imaging, and machine learning/deep learning models. All pipeline assets are sourced from this platform, including the clinical-stage lead JUV-161 (a first-in-class muscle-regenerating fusion protein with FDA Orphan Drug Designation for DM1, currently in Phase 1 trials and being expanded into sarcopenia), the preclinical metabolic program JUV-112 (an obesity biologic acting via lipid metabolism), and earlier-stage programs in IPF and hepatic disease.

Juvena Therapeutics firmographics

Firmographics
Name
Juvena Therapeutics
Legal name
Juvena Therapeutics Inc.
Website
https://juvenatherapeutics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Juvena Therapeutics is a clinical-stage biotechnology company that uses its AI-enabled JuvNET platform to engineer tissue-restorative biologics from stem-cell secreted proteins, targeting myopathies and age-related metabolic and degenerative diseases.
Ownership category
akta.pro rank

Juvena Therapeutics industry classification

Industry
Product category
Regenerative Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Tissue-restorative biologics
  • AI-enabled biologics discovery
  • Regenerative biopharmaceuticals
  • Protein engineering platform
  • Muscle regeneration therapeutics

Where Juvena Therapeutics is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Juvena Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Research Collaboration and Partnership Milestones: Pharmaceutical partnership milestone payments from research collaborations, exemplified by the Eli Lilly research collaboration agreement valued at over $650 million in potential milestone payments, focused on muscle health, body composition, and metabolic disease. Includes upfront payments, R&D funding, and contingent milestone payments plus potential royalties.
  2. Future Biologics Product Sales (Pre-Commercial): Future revenue from commercialization of tissue-restorative biologics (JUV-161 for Myotonic Dystrophy Type 1 and sarcopenia, JUV-112 for obesity/metabolic disease). Currently pre-commercial / clinical-stage with Phase 1 studies underway; no product sales revenue yet.
  3. Non-Dilutive Grant Funding: Non-dilutive grant funding from institutions including the California Institute for Regenerative Medicine (CIRM) - $3,906,376 TRAN1 grant - and NIH/National Institute on Aging support to advance lead programs and platform research.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Juvena Therapeutics product offering

Product offering

Core offering

Juvena Therapeutics is a computationally-driven biopharmaceutical company that develops tissue-restorative biologics to treat myopathies and metabolic diseases. The company operates an AI-enabled discovery and development platform (JuvNET) that mines proteins secreted by human stem cells, maps them to disease phenotypes, and engineers novel biologic medicines, with a lead clinical-stage asset (JUV-161) targeting Myotonic Dystrophy Type 1 and sarcopenia, plus preclinical programs in obesity/metabolic disease (JUV-112), idiopathic pulmonary fibrosis, and fibrotic liver disease.

Product overview

Juvena Therapeutics offers a platform-plus-pipeline architecture anchored by a single core technology — the AI-enabled JuvNET Platform — from which all of its discrete clinical and preclinical biologic assets are derived. The JuvNET Platform mines thousands of proteins secreted by human stem cells and systematically maps them to specific disease phenotypes using AI, quantitative proteomics, multi-omics, robotics-enabled high-content imaging, and protein engineering to produce tissue-restorative biologics. From this shared platform, Juvena has independently advanced a portfolio of named assets including the clinical-stage lead JUV-161 (a muscle-regenerating fusion protein in Phase 1 for Myotonic Dystrophy Type 1 with FDA Orphan Drug Designation), the preclinical metabolic program JUV-112 (an obesity asset acting via lipid metabolism), and earlier-stage programs in idiopathic pulmonary fibrosis and fibrotic liver disease. All pipeline assets are discovered and produced through the proprietary JuvNET platform and are targeted at myopathies, metabolic diseases, and broader chronic / age-related degenerative conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • JuvNET Platform: Juvena's proprietary AI-enabled end-to-end biologics drug discovery and development platform that maps secreted proteins to specific disease phenotypes, combining in silico, in vitro, in vivo, and protein engineering capabilities.

Products and services

  • JuvNET Platform AI-enabled, fully integrated biologics discovery and development platform that mines thousands of proteins secreted by human stem cells, screens their therapeutic potential across disease phenotypes using quantitative proteomics, multi-omics, and robotics-enabled high-content imaging, and engineers novel biologic medicines. Offered to biopharma partners for research collaborations and licensing.
  • JUV-161

Quantifiable outcome

  • Completed dosing in 5 of 6 SAD cohorts and all MAD cohorts in Phase 1 JUV-161 study by January 2026
  • +4 more outcomes

Companies that use Juvena Therapeutics

Customer profile

Named customers1 record

Ideal customer profiles3 records

Juvena Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Juvena Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship - flagship biopharma partnership validating platform and core - flagship patient advocacy collaboration for lead indication.

  • Eli Lilly and Companyflagship - flagship biopharma partnership validating platformStrategic or Co-development Partner · 1 June 2025Research collaboration agreement focused on muscle health, body composition, and metabolic disease, valued at over $650 million in potential milestone payments plus tiered royalties. Leverages Juvena's AI-enabled JuvNET platform and secreted protein discovery capabilities to develop novel therapeutics for muscle and metabolic indications. Featured in Nature Biotechnology for enhancing muscle health and body composition. Eli Lilly also participated in Juvena's $33.5M Series B financing in January 2026.
  • Myotonic Dystrophy Foundationcore - flagship patient advocacy collaboration for lead indicationStrategic or Co-development PartnerJuvena works together with the Myotonic Dystrophy Foundation to translate research into tangible clinical benefits for people living with DM1. The collaboration synergizes Juvena's scientific innovations with the Foundation's extensive roots in the Myotonic dystrophy community to enable profound real-world impact. CEO Dr. Tanya Stevenson of MDF endorses Juvena's approach. Joint industry presentations at MDF Annual Conference and regional summits.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Juvena Therapeutics competitors and assessment

Company assessment

Others

  • Revolution Medicines: Clinical-stage oncology biotech that grew out of a Tri-Institutional Therapeutics Discovery Institute initiative combining academic drug discovery with computational biology. Comparable as a clinical-stage biotech with strong institutional backing that has used innovative discovery approaches to advance targeted therapeutics — though focused on oncology rather than regenerative biologics.

Direct peers

  • Fate Therapeutics: Clinical-stage regenerative medicine biotech developing programmed cellular therapies from induced pluripotent stem cells. Comparable as a clinical-stage company mining stem-cell biology for novel therapeutics, though Fate's modality is cell therapy rather than engineered biologics.
  • BioAge Labs: Clinical-stage biotech using AI and omics data to develop therapeutics for age-related diseases, with focus on metabolic and muscle health. Directly comparable given the shared longevity-and-muscle therapeutic focus, AI-platform approach, and clinical stage status.
  • Surrozen: Clinical-stage biotech developing tissue-specific regenerative biologics targeting the Wnt pathway. Highly comparable in regenerative-biologics thesis, with overlap in target disease areas (hepatic, ocular) and at least one shared former team member (Priya Handa).
  • Insitro: AI-driven drug discovery platform combining machine learning, high-throughput biology, and engineered human disease models to discover novel therapeutics. Directly comparable as a clinical-stage biotech using proprietary AI/ML infrastructure to systematically map biology-to-therapeutics, though Insitro focuses more on small molecules and hepatology/neuroscience rather than biologics.
  • Scholar Rock: Clinical-stage biotech developing biologics targeting the TGFβ superfamily for muscle-related and rare diseases, including spinal muscular atrophy and obesity. Comparable as a clinical-stage biologics company pursuing muscle therapeutics — directly relevant given Juvena's JUV-161 sarcopenia program.
  • Generate Biomedicines: Generative AI biologics company using machine learning to design novel protein therapeutics de novo. Closest direct peer given the shared thesis that AI can systematically generate or engineer biologics — a precursor and parallel to Juvena's protein-library-plus-AI approach.

Broad incumbents

  • Ginkgo Bioworks: Public cell-engineering platform company that programs biological organisms for diverse applications. Comparable as a platform-plus-services biotech using AI and high-throughput biology, though Ginkgo is a much larger, broader, and more diversified incumbent focused on cell engineering rather than protein therapeutics.
  • Recursion Pharmaceuticals: Public clinical-stage biotech operating a large-scale AI-enabled drug discovery platform integrating high-throughput biology, chemistry, and ML. Comparable in platform-plus-pipeline architecture, although Recursion is a larger, public, broad-spectrum incumbent with deeper capital and broader indication coverage.
  • AbCellera Biologics: Public AI-enabled antibody discovery platform with partnership-based revenue (including major pharma collaborations). Comparable in combining an AI-driven biologics discovery engine with a partnership-centric business model, although AbCellera's focus is antibodies rather than secreted-protein-derived biologics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Juvena Therapeutics social profiles

Digital presence

Juvena Therapeutics compliance and trust

Trust signal

Compliance2 records

Juvena Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Juvena Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Juvena Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Juvena Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juvena Therapeutics

What does Juvena Therapeutics do?

Juvena Therapeutics is a computationally-driven biopharmaceutical company that develops tissue-restorative biologics to treat myopathies and metabolic diseases. The company operates an AI-enabled discovery and development platform (JuvNET) that mines proteins secreted by human stem cells, maps them to disease phenotypes, and engineers novel biologic medicines, with a lead clinical-stage asset (JUV-161) targeting Myotonic Dystrophy Type 1 and sarcopenia, plus preclinical programs in obesity/metabolic disease (JUV-112), idiopathic pulmonary fibrosis, and fibrotic liver disease.

Is Juvena Therapeutics a public or private company?

Juvena Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Juvena Therapeutics founded?

Juvena Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Juvena Therapeutics based?

Juvena Therapeutics is headquartered in Palo Alto, United States, in the North America region.

How does Juvena Therapeutics make money?

Three revenue lines are on record. Research Collaboration and Partnership Milestones are the primary driver. The others are future Biologics Product Sales (Pre-Commercial) and non-Dilutive Grant Funding.

Who are Juvena Therapeutics's main competitors?

Revolution Medicines is listed as an others. Direct peers are Fate Therapeutics, BioAge Labs, Surrozen, Insitro, Scholar Rock and Generate Biomedicines. Broad incumbents are Ginkgo Bioworks, Recursion Pharmaceuticals and AbCellera Biologics.

Does Juvena Therapeutics have an API?

No public API is recorded for Juvena Therapeutics.

What industry is Juvena Therapeutics in?

Juvena Therapeutics's product category is Regenerative Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechChutes & Ladders—Neumora shuffles leadership ahead of INDNeumora Therapeutics appointed Joshua Pinto as CEO ahead of its IND submission for an obesity treatment, while Juvena Therapeutics named Julie Anne Smith as CEO to guide phase 2 neuromuscular studies. These leadership changes are part of a broader industry roundup that also includes executive appointments at Longevica, 4C Biomed, and several other biotech firms.TipranksJuvena Therapeutics Brings In New CEO to Lead Pipeline and Team ExpansionJuvena Therapeutics has appointed biotech executive Julie Anne Smith as its new CEO to lead pipeline and team expansion. The company aims to build a high-performing organization under her leadership to advance therapeutic programs and translate assets into clinical opportunities. This strategic shift signals potential preparations for future financing, partnerships, or expanded clinical activity in the competitive biotech sector.01netJuvena Therapeutics Appoints Julie Anne Smith as Chief Executive OfficerJuvena Therapeutics has appointed Julie Anne Smith as its new Chief Executive Officer to lead the company through its next stage of growth. This leadership change coincides with the enrollment of subjects in a Phase 2a clinical trial for its AI-enabled biologic, JUV-161, which targets myotonic dystrophy. The company is also advancing its platform through a global collaboration with Eli Lilly and Company.BioSpaceJuvena Therapeutics Appoints Julie Anne Smith as Chief Executive OfficerJuvena Therapeutics appointed Julie Anne Smith as CEO and board member. The company's JUV-161 biologic is enrolling in a Phase 2a atrophy study and holds FDA Orphan Drug Designation for myotonic dystrophy. Juvena is also advancing a global collaboration with Eli Lilly to advance additional muscle and metabolic health programs.ContractpharmaJuvena Therapeutics Names Julie Anne Smith CEOJuvena Therapeutics has appointed Julie Anne Smith as its new Chief Executive Officer and Board of Directors member. This leadership change occurs as the company advances its lead asset, JUV-161, into a Phase IIa clinical trial for myotonic dystrophy. The appointment coincides with ongoing collaboration efforts with Eli Lilly Company on Juvena's proprietary discovery platform.FinSMEsJuvena Therapeutics Raises $33.5M in Series B FundingJuvena Therapeutics, a clinical-stage biotechnology company based in Redwood City, California, raised $33.5 million in Series B funding led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, Mubadala Capital, and Manta Ray. The company plans to use the proceeds to expand operations and advance its pipeline of regenerative biologics targeting neuromuscular and age-related diseases. Juvena has also initiated a search for a new Chief Executive Officer as it enters its next phase of growth.Pulse 2.0Juvena Therapeutics: $33.5 Million Series B Raised To Advance Regenerative Biologics PipelineJuvena Therapeutics raised $33.5 million in a Series B financing round led by Bison Ventures, with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing investors Mubadala Capital and Manta Ray. The funding will advance the company's clinical-stage regenerative biologics pipeline, including lead program JUV-161 currently in Phase 1 studies, and support continued development of AI-enabled discovery capabilities. The company also highlighted an existing research collaboration agreement with Eli Lilly potentially worth over $650 million in milestone payments, and announced it has initiated a search for a new chief executive officer.TechStartupsTop Startup and Tech Funding News – January 13, 2025January 13, 2026 saw approximately $885 million in startup funding across ten deals, dominated by defense tech and AI ventures, with Onebrief leading at $200 million to scale its AI mission-planning platform for U.S. military commands and Defense Unicorns raising $136 million to modernize classified government networks. Aerospace startup JetZero secured $175 million for its blended-wing aircraft demonstrator targeting commercial service in the early 2030s, while voice AI company Deepgram raised $130 million at a $1.3 billion valuation. Additional rounds included WitnessAI ($58M for enterprise AI security), Flip ($20M for vertical AI customer service), Juvena Therapeutics ($33.5M for regenerative biologics), Converge Bio ($25M for AI-driven drug discovery), Syneron Bio (~($100M) for peptide therapeutics), and Ammobia ($7.5M seed for green ammonia production).Pulse 2.0Juvena Therapeutics: $33.5 Million Series B Raised To Advance Regenerative Biologics PipelineJuvena Therapeutics raised $33.5 million in a Series B led by Bison Ventures, with participation from Eli Lilly and Jefferson Life Sciences. The funds will advance its lead muscle-regenerating biologic JUV-161, which is in Phase 1 with dosing completed in five of six cohorts. The company also highlighted a $650 million potential milestone agreement with Eli Lilly.Business Wire BlogJuvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics PipelineJuvena Therapeutics, a clinical-stage biotechnology company based in Redwood City, California, announced a $33.5 million Series B funding round led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing investors including Mubadala Capital and Manta Ray. The company is advancing Phase 1 clinical studies for its lead asset JUV-161, a first-in-class muscle-regenerating biologic, having completed dosing in five of six SAD cohorts and all MAD cohorts, with full study completion expected by end of January. The proceeds will be used to advance clinical programs, expand the pipeline of tissue-restorative biologics targeting neuromuscular and age-related diseases, and support AI-enabled discovery capabilities.